"Our problems in Asia are of mathematical nature and concern our business in Japan"

An interview with Nobel Biocare CEO Richard Laube

With a record number of 2,000 participants, dental implant solutions provider Nobel Biocare held its second Global Symposium in the US in June. Dental Tribune Asia Pacific had the opportunity to speak with CEO Richard Laube about the state of his company, business in Asia and the newly launched Foundation for Oral Rehabilitation.

DT: Mr Laube, this is the first Global Symposium you are attending as CEO of Nobel Biocare. Has the event met your expectations?

Richard Laube: So far the meeting has been a pleasant surprise for us. We were sold out already in April and even had to turn 500 to 600 customers away. On the positive side, this makes it a real special event. We were a little bit nervous about the logistics, but all went very well. Speakers have also been extremely disciplined and very focused in their messages that they wanted to convey. I am only hearing good things from the participants.

You joined Nobel Biocare during turbulent times. What is the state of the company compared to when you took over as CEO in 2011?

It is true that we have been drifting over the years but we are back with patient-focused, clinically-relevant and evidence-based innovation. We are materially better today than we were two years ago. The results from Q1/2015 were a pleasant surprise as we expected the numbers to be lower. We also have a couple of new announcements here. All this combined offers probably the most exciting product line-up in the industry and provides us with the opportunity of leading again.

We also have a couple of new announcements here. All this combined offers probably the most exciting product line-up in the industry and provides us with the opportunity of leading again.

With the DENTSPLY-Astra Tech merger and growing competition from manufacturers in Asia, e.g. Korea, the implant market seems to be on the brink of major change. How do you evaluate the development of the market and how is your company positioning itself in the market?

Our problems in Asia are of mathematical nature and concern our business in Japan which used to provide 17 per cent of our total business in the region. Difficulties there were in part market-inflicted through the tsunami and the negative press on dental implants in 2012, in part self-inflicted as we were a little bit fooled by the positive numbers in prosthetics in the first quarter of that year, not looking at the implants that were actually going down. As we are seeing the implants rebound, I think we will have a good run in the second half of this year.

One of the highlights of the recent past, we have not taken on that challenge of helping dentists learn how to place implants properly. These are opportunities where we can also contribute to the growth of the total market.

With the NobelProcera 2G Scanner and a new open access partnership with iShape you have recently consolidated your foothold in dental CAD/CAM. How important has this field become for your company and will we see new products to be introduced for this segment in the future?

CAD/CAM is critical. Patients just do not necessarily want implants, they really want teeth. Our ability to provide them with teeth in complex reconstructions is a huge competitive advantage. If you are dealing with anything more than a three- or four-unit bridge. We have a disproportionate market share in what we call complex screw-retained componentry. We can put together a 12-unit maxilla implant bridge with eight holes for screws, for example, in a way that is very difficult to replicate by our competition.

Besides new third-party platforms, implant bridges and scanning design centers we presented at IDS in Cologne this year, we are announcing angulated screw channels here in New York. With this subtle but almost revolutionary development, we can now go in by 25 degrees, which makes it better for the patient, for the site, or the tongue site and make access to screw-retained components much easier.

With the DENTSPLY-Astra Tech merger and growing competition from manufacturers in Asia, e.g. Korea, the implant market seems to be on the brink of major change. How do you evaluate the development of the market and how is your company positioning itself in the years to come?

We welcome any competition as it is beneficial for patients. Our challenge is to stay ahead and innovate. Implant dentistry is still an emerging field that is emerging rapidly and transforming itself constantly through innovation. Our aspiration is to stay in front of that.

How does your company intend to return to sustainable growth?

We grow when customers order from us and these customers are starting ordering more when we are doing good things for them in the area of innovation, commercial relationship partnering programs, as well as in training and the education that we provide to allow them to treat more patients and do new things. It is a fact that there are only 11 to 12 per cent of licensed dentists in the world that are placing dental implants. In the recent past, we have not taken on that challenge of helping dentists learn how to place implants properly. These are opportunities where we can also contribute to the growth of the total market.

"Our problems in Asia are of mathematical nature and concern our business in Japan"